Financial Performance - FY25 Net Sales reached $2,904 million, aligning with the guidance of $2,900 - $2,975 million[8] - FY25 Adjusted EBITDA was $889 million, within the guidance range of $880 - $920 million[8] - FY25 Adjusted EBITDA Margin was 30.6%, meeting the guidance of 30.3% - 30.9%[8] - Infiltrator's FY25 revenue increased by 15% to $516 million from $449 million in FY24[20] - Infiltrator's Adjusted Gross Profit margin improved by 60 bps to 53.6% in FY25 from 53.0% in FY24[23] - Consolidated Free Cash Flow was $369 million in FY25, compared to $534 million in FY24[29] Segment Performance and Product Mix - Allied Products and Pipe segments accounted for 56.2% and 26% of FY25 revenue, respectively[11] - Infiltrator segment accounted for 18% of FY25 revenue[11] - Infiltrator's organic advanced treatment business grew by 33% year-over-year[25] Fiscal 2026 Expectations - The company anticipates Net Sales between $2,825 million and $2,975 million for Fiscal Year 2026, representing a (3%) to +2% change[31] - The company projects Adjusted EBITDA between $850 million and $910 million for Fiscal Year 2026, a (4%) to +2% change[31] - The company expects Adjusted EBITDA Margin between 30.1% and 30.6% for Fiscal Year 2026, a (50) bps to flat change[31]